Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2002

View Archived Issues

Novel diazoxide analogue preserves beta-cell function

TLK-19780, a nonpeptide insulin receptor activator

Glucose concentration-dependent insulin secretion potentiators identified at Kyowo Hakko

AndroGel continues to provide benefits in hypogonadal men for up to 42 months

MMP-targeting NeuGene antisense agent inhibits prostate cancer growth

Selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor effective in type 2 diabetes model

GW-3965, a synthetic LXR ligand, displays potent antiatherogenic activity

Antiinflammatory activity of IS-741 in experimental colitis

Australia first to approve Xolair

Potent in vitro activity of ravuconazole and voriconazole against Candida spp.

Inflazyme reports on development of key LSAIDs

Cytovax updates progress of key product candidates

Synthesis and therapeutic applications of glucocorticoid receptor modulators

Plexus Vaccine establishes subsidiary for new vaccine development

Celgene and Novartis advance SERM osteoporosis program

Genelabs permitted to seek E.U. approval for Aslera under centralized procedure

Tanox outlicenses Bak gene

Xenerex awarded funding for development of anthrax therapy

UCB presents R&D overview

New agents for HIV identified at Parker Hughes Institute

Recent patent covers new PDE5 inhibitors designed at Lilly Icos

Novartis presents new PKC inhibitors and use in autoimmune diseases, cancer, etc.

Pyrimidine NPY receptor antagonists useful for obesity

Calcilytic compounds in development at GSK for osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...